title: Nanoparticle technology for treatment of Parkinson's disease: the role of surface phenomena in reaching the brain.
abstract: The absence of a definitive treatment for Parkinson's disease has driven the emerging investigation in the search for novel therapeutic alternatives. At present, the formulation of different drugs on nanoparticles has represented several advantages over conventional treatments. This type of multifunctional carrier, owing to its size and composition, has different interactions in biological systems that can lead to a decrease in ability to cross the blood-brain barrier. Therefore, this review focuses on the latest advances in obtaining nanoparticles for Parkinson's disease and provides an overview of technical aspects in the design of brain drug delivery of nanoparticles and an analysis of surface phenomena, a key aspect in the development of functional nanoparticles for Parkinson's disease.
authors.affiliation: Laboratory of Connective Tissue, CENIAQ, Instituto Nacional de Rehabilitación (INR), Mexico City, Mexico.
authors.forename: Gerardo
authors.initials: G
authors.lastname: Leyva-Gómez
authors.affiliation: Laboratory of Genomic Medicine, Department of Genetics, Instituto Nacional de Rehabilitación (INR), Mexico City, Mexico.
authors.forename: Hernán
authors.initials: H
authors.lastname: Cortés
authors.affiliation: Laboratory of Genomic Medicine, Department of Genetics, Instituto Nacional de Rehabilitación (INR), Mexico City, Mexico.
authors.forename: Jonathan J
authors.initials: JJ
authors.lastname: Magaña
authors.affiliation: Laboratory of Genomic Medicine, Department of Genetics, Instituto Nacional de Rehabilitación (INR), Mexico City, Mexico.
authors.forename: Norberto
authors.initials: N
authors.lastname: Leyva-García
authors.affiliation: Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Laboratorio de Posgrado en Tecnología Farmacéutica, Av. 1o de mayo s/n, Cuautitlán Izcalli, C.P. 54745, Edo de México, Mexico. Electronic address: quintana@unam.mx.
authors.forename: David
authors.initials: D
authors.lastname: Quintanar-Guerrero
authors.affiliation: Department of Physiology, Biophysics & Neuroscience, Centro de Investigación y de Estudios Avanzados-IPN (CINVESTAV-IPN), Mexico City, Mexico.
authors.forename: Benjamín
authors.initials: B
authors.lastname: Florán
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism*; D001812:Blood-Brain Barrier / Q000378:metabolism*; D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers; D006801:Humans; D050997:Nanomedicine; D053758:Nanoparticles; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D010539:Permeability; D011108:Polymers / Q000737:chemistry*; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000379:methods*
chemical_list: D000978:Antiparkinson Agents; D004337:Drug Carriers; D011108:Polymers